Author: admin

ODIN Partners With TorFX to Help Australian Expats Eliminate Up to $7,500 in Hidden Bank Fees on Property Transfers

ODIN, the Australian expat property firm serving over 2,000 clients across 40 countries, has formalised TorFX as its official foreign exchange referral partner. The partnership addresses a persistent cost gap in cross-border property transactions, where buyers routinely lose thousands of dollars to invisible bank margins.

Australian expatriates typically transfer between $300,000 and $500,000 across borders during a single property transaction to cover deposits, settlement funds, renovation budgets, and ongoing rental income. Most buyers default to their primary bank for these transfers, unaware that banks typically apply a 2 to 3 percent margin built directly into the exchange rate rather than appearing as a line-item fee on statements.

On a $300,000 transfer, the difference between a standard bank rate and a specialist provider rate can exceed $7,500.

“FX is one of the biggest hidden costs in the expat property equation,” said Ben Wong, Co-founder of ODIN. “On a $300,000 deposit transfer, the difference between a bank rate and a specialist rate can be $7,500 or more. That’s real money that should be going into the property position, not disappearing into a spread.”

The partnership gives ODIN clients access to competitive international transfer rates, dedicated account management, and a full AUD$100 credit applied directly to their account on their first transfer of more than AUD$2,000. TorFX, which processes more than $20 billion in annual transactions, charges no transfer fees and provides tools such as forward contracts and limit orders that allow buyers to lock in rates ahead of settlement

TorFX is regulated by the Australian Securities and Investments Commission (ASIC) and the Australian Transaction Reports and Analysis Centre (AUSTRAC), with client funds held at JPMorgan, Barclays, and Citi. The firm has operated for over 20 years across 25 global offices and held Canstar’s 5-Star rating for seven consecutive years from 2018 to 2024.

For ODIN, the addition of a formal FX referral partner completes its integrated service model. The firm already combines mortgage brokerage, tax advisory, and conveyancing for Australian expats and foreign investors. With TorFX, ODIN now covers every major financial touchpoint in the property purchase process, from initial borrowing power assessment through to settlement and ongoing rental income management.

ODIN clients can register with TorFX through a dedicated referral link, with account setup taking approximately 20 to 30 minutes and transfers typically landing within 24 to 48 hours.

About ODIN

ODIN is a specialized financial services firm dedicated to Australian citizens, permanent residents, and foreign investors living overseas. Headquartered in Hong Kong with a strong presence in Singapore, ODIN provides an integrated suite of mortgage, tax, and legal services, enabling clients to buy and manage Australian property from anywhere in the world. The firm combines proprietary lending data on more than 40 Australian lenders with specialist tax knowledge across major expat corridors. ODIN has successfully served over 2,000 clients globally.

Disclaimer: This article contains general information only and does not constitute personalised financial, tax, or legal advice. ODIN has a referral relationship with TorFX. ODIN is regulated under the Australian Securities and Investments Commission (ASIC) and the National Consumer Credit Protection Act (NCCP). ODIN Tax operates under the Tax Practitioners Board (TPB).

Media Contact
Company Name: ODIN
Contact Person: Ben Wong
Email: Send Email
Country: HongKong
Website: https://www.odinmortgage.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ODIN Partners With TorFX to Help Australian Expats Eliminate Up to $7,500 in Hidden Bank Fees on Property Transfers

Woodland Hills HVAC Contractor Discounts Whole-Home Air Scrubber to $875 as Wildfire Smoke Blankets Los Angeles County

“”When your AC kicks on during a fire, it pulls smoke into your home and pushes it through every vent. A standard furnace filter does almost nothing against wildfire smoke particles. The Air Scrubber destroys what filters can’t – smoke, VOCs, and the odor that lingers for weeks. Families who have these installed tell us they sleep through the night while their neighbors are coughing.” – Matthew Stupak, Marketing Director, LA Heating and Air Conditioning.”
LA Heating and Air Conditioning reduces Aerus Air Scrubber installation from $1,250 to $875 for 30 days as smoke from the Sandy Fire, Bain Fire, and other active wildfires triggers air quality advisories across Los Angeles and San Fernando Valley. The whole-home air purification system installs into existing HVAC ductwork and uses ActivePure technology to neutralize PM2.5 smoke particles, VOCs, and odor throughout the entire house. Same-day installation available in San Fernando Valley.

WOODLAND HILLS, CA – Jun 1, 2026 – With smoke from the Sandy Fire in Simi Valley, the Bain Fire in Riverside County, and multiple other active wildfires drifting across Southern California, LA Heating and Air Conditioning is reducing the installed price of the Aerus Air Scrubber from $1,250 to $875 for the next 30 days to help Los Angeles families keep their indoor air safe.

The South Coast Air Quality Management District has issued smoke advisories this week covering Los Angeles, Ventura, Riverside, and San Bernardino counties. Health officials are urging residents to stay indoors. But staying indoors may not be enough.

YOUR AC SYSTEM MAY BE MAKING INDOOR AIR WORSE

Most homeowners close their windows during smoke events and assume their home is protected. The opposite is often true. Standard residential HVAC systems pull outdoor air through return vents and ductwork, circulating smoke particles throughout every room in the house each time the system cycles.

“The standard one-inch furnace filter in most LA homes is rated MERV 8 or lower. It catches dust and pet hair. It does almost nothing against the fine particulate matter in wildfire smoke, says Matthew Stupak, Marketing Director, LA Heating and Air.”

PM2.5 particles, the most dangerous component of wildfire smoke, are small enough to pass through standard air filters, penetrate deep into the lungs, and enter the bloodstream. The EPA reports that during major wildfire events, indoor PM2.5 concentrations can reach two to five times higher than outdoor levels because particles settle into duct systems and recirculate with every fan cycle.

WHAT THE AIR SCRUBBER DOES DIFFERENTLY

Unlike portable air purifiers that clean a single room, the Aerus Air Scrubber installs directly into the home’s existing HVAC ductwork and uses ActivePure technology to neutralize smoke particles, volatile organic compounds, ash residue, and odor throughout the entire house. The system runs automatically whenever the HVAC operates. There are no filters to replace and no maintenance required.

“Portable HEPA filters are better than nothing, but families end up crowding into one bedroom with a single unit while the rest of the house fills with smoke,” Stupak said. “The Air Scrubber cleans the air in every room, including bedrooms where your kids sleep. That is the difference families notice immediately.”

Customers who have the system installed report sleeping through the night during smoke events without irritation, even when neighbors in the same block are dealing with smoke odor and eye irritation inside their own homes.

MOST VULNERABLE RESIDENTS NEED MORE THAN A CLOSED WINDOW

The California Air Resources Board has documented that wildfire smoke causes disproportionate harm to children under 12, adults over 65, pregnant women, and anyone with asthma, COPD, or cardiovascular conditions. PM2.5 particles bypass the body’s normal defenses and enter the bloodstream directly through the lungs.

“We are offering this discount because families need protection right now, not next month,” Stupak said. “A parent with an asthmatic child should not have to choose between their budget and their kid being able to breathe at night.”

Residents across the San Fernando Valley, Calabasas, Pacific Palisades, Malibu, Woodland Hills, Encino, Sherman Oaks, Tarzana, Northridge, Van Nuys, Studio City, Burbank, Glendale, and surrounding communities are affected by current smoke conditions.

AIR SCRUBBER VS. PORTABLE FILTER VS. HEPA FURNACE FILTER

For homeowners weighing their options during active smoke events:

A portable air purifier pulls air through a HEPA filter in one room. It helps that single room but does nothing for the rest of the house. Cost: $200 to $800 per unit, per room.

A MERV 13 or higher furnace filter captures up to 95 percent of PM2.5 in the airflow but does not remove smoke odor or volatile organic compounds. During active fire events, these filters clog within days. Cost: $30 to $80 per filter, replaced frequently during fire season.

The Aerus Air Scrubber actively destroys smoke particles, VOCs, and odor compounds at the duct level using ActivePure technology. It provides continuous 24-hour coverage throughout the entire home, up to 3,000 square feet. It addresses smoke odor, which standard filtration cannot. Cost: $875 installed through LA Heating and Air for the next 30 days (regular price $1,250).

For the strongest protection, Stupak recommends pairing a high MERV filter with an Air Scrubber. The filter catches the larger particles. The Air Scrubber destroys what gets through, plus the smoke odor that no filter can touch.

PRICING, AVAILABILITY, AND INSTALLATION

The Aerus Air Scrubber is available fully installed for $875 (regular price $1,250) for the next 30 days. Installation takes less than two hours and works with any existing central HVAC system. No modifications to the home are required. Same-day and next-day installation is available across Los Angeles County, Ventura County, and the San Fernando Valley.

Homeowners can learn more or schedule installation at www.laheatingairconditioning.com/air-scrubber-los-angeles or by calling (818) 660-1062.

ABOUT LA HEATING AND AIR CONDITIONING

LA Heating and Air Conditioning is a family-owned HVAC contractor (California Contractor License No. 952950, EPA Section 608 Certified, TECH Clean California Certified) serving the San Fernando Valley and greater Los Angeles area since 2009. The company specializes in residential and commercial AC repair, AC replacement, heat pump installation, indoor air quality, and HVAC maintenance. With over 700 five-star Google reviews and a 4.9 average rating, LA Heating and Air has served notable clients including Westfield Topanga Mall, Northridge Fashion Center, and LA Family Housing. Located at 6430 Variel Ave, Suite 102, Woodland Hills, CA 91367.

Media Contact
Company Name: LA Heating and Air
Contact Person: Matthew Stupak
Email: Send Email
Phone: (818) 660-1062
Address:7710 Atron Avenue
City: Woodland Hills
State: https://www.laheatingairconditioning.com/
Country: United States
Website: https://www.laheatingairconditioning.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Woodland Hills HVAC Contractor Discounts Whole-Home Air Scrubber to $875 as Wildfire Smoke Blankets Los Angeles County

El Dorado Insurance Launches Certificate Hero, Giving Clients 24/7 Self-Service Access to Certificates of Insurance

New secure online portal lets policyholders create, customize, and send Certificates of Insurance on their own schedule, eliminating delays and reducing administrative friction.

El Dorado Insurance Agency, Inc., a nationally recognized provider of insurance solutions for the private security industry and other specialty risk categories, today announced that clients now have direct access to Certificate Hero, a secure online portal that allows policyholders to create and send their own Certificates of Insurance (COIs) anytime, day or night. The launch marks a significant step forward in El Dorado’s ongoing commitment to client service, technology investment, and operational efficiency.

Putting Certificates of Insurance in the Client’s Hands

Certificates of Insurance are a routine but business-critical document. They prove that coverage is in force, list policy limits, and are often required before a contractor can step onto a job site, a vendor can sign a contract, or a security company can begin work for a new client. For many small and mid-sized businesses, the process of requesting a COI from their agency has historically meant a phone call, an email, or a fax, followed by a wait that could last hours or even days.

With Certificate Hero, El Dorado clients can log in to a secure portal and generate the COI they need on demand. Users can select the policies to reference, add a certificate holder, customize details where their coverage allows, and email the finished certificate directly to the requesting party. The portal is available 24 hours a day, seven days a week, removing the dependency on agency business hours and giving clients a faster path to closing new business.

“Our clients are out winning contracts, mobilizing teams, and responding to opportunities that often appear with very little notice,” said the El Dorado Insurance team. “Certificate Hero is about meeting them where they are. If a security firm gets a call at 9 p.m. asking for proof of insurance before a Saturday event, they should not have to wait until Monday morning to send it. Now they do not have to.”

Why This Matters for the Industries El Dorado Serves

El Dorado Insurance has spent decades specializing in coverage for industries where speed and documentation are essential, including private security, investigations, alarm and monitoring companies, process servers, and other specialty operators. According to research highlighted by the Insurance Information Institute, small businesses across the country increasingly expect their insurance providers to deliver the same digital convenience they get from their banks, payroll providers, and software vendors. Self-service COI tools have become one of the clearest signals that an agency is investing in that experience.

The Certificate of Insurance itself is governed in most states by standardized forms maintained by ACORD, the global standards body for the insurance industry. Certificate Hero generates ACORD-compliant certificates, ensuring that the documents El Dorado clients send out are accepted by general contractors, municipalities, property managers, and other certificate holders without delay or rework.

For security operators in particular, the ability to issue a COI quickly can be the difference between winning and losing a contract. Industry coverage from outlets such as Security Magazine has noted that procurement teams are increasingly tightening insurance verification requirements and shortening response windows. Tools like Certificate Hero help El Dorado clients meet those expectations without adding administrative staff.

Built-In Security and Oversight

While self-service is the headline feature, El Dorado designed the Certificate Hero rollout with appropriate guardrails. Clients can only generate certificates that accurately reflect the coverage in force on their policies, and the agency retains full visibility into every certificate issued through the portal. That combination gives clients control over their day-to-day documentation needs while preserving the compliance and audit trail that insurance carriers and regulators expect.

Access to Certificate Hero is provided to eligible El Dorado clients at no additional cost. Onboarding is straightforward: clients receive credentials, a short orientation to the portal, and ongoing support from the El Dorado service team if they encounter questions. The portal is accessible from any modern web browser on a desktop, tablet, or mobile device.

Part of a Broader Investment in Client Experience

The Certificate Hero rollout is the latest in a series of client experience improvements El Dorado has announced through its resource center and email newsletters, including the most recent client update. The Resource Center brings together educational content, compliance guidance, and tools designed specifically for the industries El Dorado serves, with the goal of helping policyholders run safer, smarter, and more profitable operations.

“Insurance is not just about the policy you buy on day one,” the El Dorado team added. “It is about how easy your agency makes it for you to actually use that coverage when you need it. Certificate Hero is one more way we are trying to make that part of the relationship effortless.”

Getting Started

Current El Dorado Insurance clients who have not yet been onboarded to Certificate Hero can visit the El Dorado Resource Center to learn more and request access. Prospective clients interested in coverage for private security, investigations, alarm services, and other specialty industries are invited to contact El Dorado for a consultation and quote.

About El Dorado Insurance Agency

El Dorado Insurance Agency, Inc. is one of the most established providers of insurance solutions for the private security industry and related specialty risk categories in the United States. Headquartered in Houston, Texas, the agency serves thousands of clients across the country and is known for its deep industry expertise, long-standing carrier relationships, and commitment to client service. El Dorado offers a comprehensive portfolio of coverages including general liability, professional liability, workers compensation, commercial auto, bonds, and more, supported by tools like Certificate Hero that make day-to-day insurance administration easier for busy operators.

Media Contact
Company Name: El Dorado Insurance
Contact Person: Andy Ring
Email: Send Email
Phone: 1-800-221-3386
Address:3673 Westcenter Dr
City: Houston
State: https://eldoradoinsurance.com
Country: United States
Website: https://eldoradoinsurance.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: El Dorado Insurance Launches Certificate Hero, Giving Clients 24/7 Self-Service Access to Certificates of Insurance

Blue Atlas Marketing Celebrates 15 Years of Digital Excellence with Renewed Focus on Website Accessibility

Blue Atlas Marketing marks milestone anniversary by expanding ADA compliance services to help businesses build inclusive digital experiences.

Blue Atlas Marketing, a full-service digital marketing agency known for partnering with industrial, manufacturing, and B2B brands across the country, today announced the celebration of its 15-year anniversary alongside a renewed strategic focus on website accessibility and ADA compliance services. The milestone reflects a decade and a half of evolving alongside its clients and a deepening commitment to building digital experiences that work for everyone.

Fifteen Years of Growing With Clients

Founded in 2011, Blue Atlas Marketing has spent the past 15 years helping companies translate complex products and services into clear, measurable marketing results. What began as a small team focused on website design and search engine optimization has grown into a full-service agency offering brand strategy, web development, paid media, content marketing, video production, and analytics. Throughout that growth, the company has maintained the same client-first philosophy that shaped its earliest engagements.

“Reaching 15 years in this industry is something we don’t take for granted,” said the Blue Atlas leadership team. “Digital marketing has changed dramatically since 2011, but our purpose has stayed the same: to help our clients communicate clearly, reach the right audiences, and grow with confidence. The next chapter of Blue Atlas is about extending that mission to people who have too often been left out of the digital conversation.”

A Strategic Shift Toward Website Accessibility

As part of its anniversary year, Blue Atlas is formally expanding its ADA website compliance services, a practice area the agency has been quietly building over recent years. The expansion responds to a clear and growing need: more than one billion people worldwide live with some form of disability, according to the World Health Organization, and yet the vast majority of websites still fail basic accessibility tests.

The 2024 WebAIM Million report found that 95.9 percent of the top one million home pages had detectable Web Content Accessibility Guidelines (WCAG) failures, with an average of more than 56 errors per page. At the same time, ADA-related digital accessibility lawsuits have continued to climb year over year, creating both a moral and a legal imperative for businesses to act.

Blue Atlas’s expanded accessibility practice helps clients audit their existing sites against the latest WCAG 2.2 standards, remediate code and content issues, and build new sites that are accessible from day one. Services include manual and automated audits, keyboard and screen reader testing, color contrast and typography reviews, alt text and structured content development, ongoing monitoring, and team training.

Why Accessibility, and Why Now

The shift comes at a pivotal moment for U.S. businesses. In April 2024, the U.S. Department of Justice issued a final rule under Title II of the ADA requiring state and local governments to make their web content and mobile apps conform to WCAG 2.1 Level AA. While the rule applies directly to public entities, it has accelerated expectations across the private sector, where courts have increasingly treated commercial websites as places of public accommodation under Title III.

Industry data underscores the urgency. According to accessibility law firm Seyfarth Shaw, thousands of ADA Title III website accessibility lawsuits are filed each year in federal court, with retail, hospitality, food service, and professional services among the most frequently targeted industries. Settlements regularly include not just financial damages but also mandated remediation timelines and ongoing monitoring.

Beyond compliance, accessibility is increasingly recognized as a driver of usability, search performance, and brand trust. Properly structured headings, descriptive link text, captioned video, and meaningful alt attributes also benefit search engines and users on mobile devices, slow connections, or in noisy environments. Blue Atlas frames accessibility not as a checkbox exercise but as a long-term investment in digital quality.

“Accessibility is good business and it is the right thing to do,” the agency noted. “When a site is built well for someone using a screen reader, it tends to be built well for everyone. Our clients are seeing that the same work that protects them legally also makes their sites faster, clearer, and easier to convert on.”

Looking Ahead to the Next 15 Years

In addition to expanding its accessibility services, Blue Atlas is investing in tooling, internal training, and partnerships with assistive technology users to ensure its recommendations reflect real-world experience rather than automated scans alone. The agency is also developing educational resources for clients and the broader marketing community, including guides on WCAG fundamentals, accessible content writing, and the business case for inclusive design.

The 15-year anniversary will be marked throughout 2026 with client appreciation initiatives, new case studies, and content highlighting the people and partnerships that have shaped the company. Blue Atlas remains headquartered in Houston and continues to serve clients nationally across industries including manufacturing, energy, healthcare, professional services, and consumer brands.

Schedule a Consultation

Businesses interested in evaluating their current website for accessibility, learning more about WCAG 2.2 conformance, or discussing a broader digital strategy can schedule a free consultation with the Blue Atlas team. Initial consultations include a high-level review of accessibility risk areas and recommendations tailored to the organization’s size, industry, and goals.

About Blue Atlas Marketing

Blue Atlas Marketing is a Houston-based, full-service digital marketing agency celebrating 15 years of helping businesses grow through strategic websites, search marketing, content, video, and brand development. The agency partners with B2B and industrial clients across North America to design measurable marketing programs and accessible digital experiences.

Media Contact
Company Name: Blue Atlas Marketing
Contact Person: Nathaniel Stockard
Email: Send Email
Phone: 713-244-6643
Address:11601 Shadow Creek Parkway Ste 111-372
City: Pearland
State: https://www.blueatlasmarketing.com
Country: United States
Website: https://www.blueatlasmarketing.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Blue Atlas Marketing Celebrates 15 Years of Digital Excellence with Renewed Focus on Website Accessibility

Buck Stove & Spa Brings Bloom™ Hot Tubs to Visalia, Offering a Modern Approach to Backyard Relaxation

“A modern outdoor hot tub is shown in a stylish backyard setting, surrounded by comfortable patio furnishings and warm ambient lighting. The spa features clean contemporary lines and inviting blue water, creating a relaxing atmosphere designed for wellness and everyday enjoyment. The setting highlights the comfort, simplicity, and approachable luxury of the Bloom™ hot tub collection, showcasing a space ideal for unwinding with family or enjoying peaceful evenings at home.”
Buck Stove & Spa has introduced the Bloom™ hot tub collection to homeowners in Visalia and the Central Valley. Designed for comfort, simplicity, and modern backyard living, Bloom hot tubs offer an approachable spa ownership experience with hydrotherapy benefits, energy-conscious design, and stylish aesthetics. The new collection is now available at Buck Stove & Spa’s Visalia showroom, where customers can explore models and receive expert guidance.

VISALIA, Calif. – Jun 1, 2026 – As more homeowners invest in creating comfortable and enjoyable outdoor living spaces, Buck Stove & Spa is proud to introduce the Bloom™ hot tub collection to customers throughout Visalia and the Central Valley. Designed with simplicity, comfort, and modern styling in mind, Bloom hot tubs offer homeowners a fresh way to enjoy relaxation and wellness at home.

The demand for outdoor living improvements continues to grow as homeowners look for ways to maximize the enjoyment of their property. Hot tubs remain one of the most popular backyard upgrades, providing a convenient space for relaxation, family time, and personal wellness. The Bloom collection is designed to meet that demand with approachable spa ownership and a focus on everyday comfort.

Unlike many oversized luxury spas that can feel complicated or intimidating for first-time buyers, Bloom hot tubs emphasize ease of use, practical features, and modern aesthetics. The collection is designed to fit naturally into a variety of outdoor environments, from compact patios to larger backyard entertainment spaces.

“Many homeowners are looking for ways to create a relaxing retreat right in their own backyard,” said a representative of Buck Stove & Spa. “The Bloom collection offers a modern approach to hot tub ownership by focusing on comfort, simplicity, and everyday enjoyment. It’s a great fit for homeowners who want the benefits of a spa without unnecessary complexity.”

Bloom hot tubs are designed to appeal to a wide range of homeowners, including first-time spa buyers, couples seeking a private relaxation space, and families looking to enhance their outdoor living areas. With comfortable seating configurations, hydrotherapy-focused jet placement, and energy-conscious design, the collection delivers a balance of performance and practicality.

The introduction of Bloom hot tubs aligns with broader outdoor living trends seen throughout California. Homeowners continue to prioritize projects that improve quality of life, increase enjoyment of their property, and create opportunities to spend more time outdoors. Backyard wellness spaces have become an increasingly popular part of that trend.

Industry experts note that hydrotherapy may help promote relaxation and ease muscle tension, making hot tubs a popular addition for homeowners seeking stress relief and recovery after long workdays or physical activity. Bloom hot tubs are designed to support those lifestyle goals while maintaining a straightforward ownership experience.

As a locally owned and operated business serving Visalia and surrounding communities, Buck Stove & Spa provides customers with more than just products. The company offers personalized guidance, showroom consultations, delivery coordination, water care support, and ongoing service to help homeowners get the most from their investment.

Customers interested in learning more about the Bloom collection can visit the Buck Stove & Spa showroom in Visalia to compare models, discuss installation options, and receive recommendations based on their backyard space and lifestyle goals.

More information about the Bloom collection is available at:

https://buckstoveandspas.com/bloom/

About Buck Stove & Spa

Buck Stove & Spa is a leading provider of hot tubs, fireplaces, pellet stoves, outdoor living products, and related services in Visalia, California. The company serves homeowners throughout the Central Valley with a commitment to quality products, knowledgeable customer service, and ongoing support. Buck Stove & Spa helps customers create comfortable indoor and outdoor living environments through trusted brands and expert guidance.

Website: https://buckstoveandspas.com/

Media Contact
Company Name: Buck Stove & Spa
Contact Person: Bob Haun
Email: Send Email
Phone: (559) 627-2205
Address:1830 W Caldwell Ave
City: Visalia
State: www.buckstoveandspas.com
Country: United States
Website: www.buckstoveandspas.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Buck Stove & Spa Brings Bloom™ Hot Tubs to Visalia, Offering a Modern Approach to Backyard Relaxation

Jobnova.ai Introduces AI Job Search Platform to Help Candidates Find and Apply to Jobs Faster

“Jobnova.ai provides AI-powered job search tools designed to help candidates discover relevant roles, improve their resumes, and manage applications more efficiently.”
Jobnova.ai helps job seekers streamline their job search with AI job matching, smart job recommendations, instant job notifications, resume customization, and auto-apply tools.

United States – Jun 1, 2026 – Jobnova.ai has announced an AI-powered job search platform designed to help candidates find relevant opportunities, customize resumes, and manage applications more efficiently.

The platform’s AI job search tools combine job matching, smart recommendations, instant job notifications, resume customization, and auto-apply support to reduce the repetitive work involved in modern job hunting.

For many job seekers, applying for jobs has become a time-consuming process that often requires searching across multiple job boards, rewriting resumes for different roles, tracking applications manually, and responding quickly when new openings appear. Jobnova.ai was created to help candidates simplify that workflow and make the job search process more structured, focused, and efficient.

The platform uses AI to help users identify roles that better match their background, skills, and career goals. Instead of relying only on manual search, candidates can use Jobnova.ai to discover relevant opportunities and organize the application process in one place. This is especially useful for job seekers who are applying to multiple positions and need a faster way to keep track of their progress.

Resume customization is another core part of the platform. Many candidates send the same resume to every employer, even though different roles often require different keywords, experiences, and positioning. Jobnova.ai helps users adapt their resumes for specific job opportunities, giving candidates a more targeted way to present their qualifications.

“Job seekers should not have to spend hours repeating the same tasks across different job sites,” said a spokesperson for Jobnova.ai. “Our goal is to help candidates move faster, apply smarter, and stay organized throughout the job search process.”

Jobnova.ai is built for active job seekers who want to save time, improve resume relevance, and avoid missing new job opportunities. With features such as AI job matching, smart job recommendations, instant job alerts, and application support, the platform helps users respond to opportunities more quickly while maintaining a clear overview of their job search.

The company believes AI can play a practical role in reducing friction during the hiring journey. Rather than replacing the candidate’s own judgment, Jobnova.ai is designed to support better decision-making, stronger applications, and more consistent follow-up.

Jobnova.ai is now available online for job seekers looking for a smarter way to manage their search from job discovery to application.

About Jobnova.ai

Jobnova.ai is an AI-powered job search platform designed to help candidates find relevant jobs, customize resumes, receive job alerts, and apply more efficiently. The platform combines AI job matching, smart recommendations, resume support, and application tools to help job seekers manage the job search process from discovery to application.

Media Contact
Company Name: Jobnova.ai
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://jobnova.ai/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Jobnova.ai Introduces AI Job Search Platform to Help Candidates Find and Apply to Jobs Faster

Mantle Cell Lymphoma Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s “Mantle Cell Lymphoma Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Mantle Cell Lymphoma pipeline landscape. It covers the Mantle Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mantle Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Mantle Cell Lymphoma Pipeline? @ https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight

Key Takeaways from the Mantle Cell Lymphoma Pipeline Report

  • On May 22, 2026- BeOne Medicines announced a phase 3 study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
  • On May 18, 2026- Acerta Pharma BV conducted a clinical trial is a Phase 2, multicenter, (approximately 70 global centers), open-label study in subjects with histologically documented MCL, who have relapsed after, or were refractory to, ≥ 1 (but not > 5) prior treatment regimens. Subjects will be enrolled and will take 100 mg of acalabrutinib twice per day (BID) in repeated 28-day cycles.
  • On May 18, 2026- BeOne Medicines announced a phase 3 study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.
  • On May 15, 2026- Loxo Oncology Inc. initiated a phase 3 study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress.
  • On May 14, 2026- Canadian Cancer Trials Group conducted a phase II study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma.
  • DelveInsight’s Mantle Cell Lymphoma Pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Mantle Cell Lymphoma treatment.
  • The leading Mantle Cell Lymphoma Companies such as Roche, Merck Sharp & Dohme LLC, OncoNano Medicine, Inc., March Biosciences, Wellington Zhaotai Therapies Limited, Regeneron Pharmaceuticals, Nurix Therapeutics, Inc., Cellectar Biosciences, Inc., Adicet Therapeutics, Oncternal Therapeutics, Inc., AstraZeneca, Atara Biotherapeutics, Accutar Biotechnology Inc., AbbVie, Galapagos NV and others.
  • Promising Mantle Cell Lymphoma Therapies such as Lenalidomide, Obinutuzumab, Glofitamab, Ibrutinib, Rituximab, Ibrutinib, Pirtobrutinib, Acalabrutinib, and others.

Want to know which companies are leading innovation in Mantle Cell Lymphoma? @ Mantle Cell Lymphoma Clinical Trials Assessment

The Mantle Cell Lymphoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Mantle Cell Lymphoma Pipeline Report also highlights the unmet needs with respect to the Mantle Cell Lymphoma.

Mantle Cell Lymphoma Overview

Mantle cell lymphoma (MCL) is a rare and aggressive form of B-cell non-Hodgkin lymphoma, primarily distinguished by the characteristic t (11; 14) chromosomal translocation, leading to the overexpression of cyclin D1. This genetic alteration drives the uncontrolled proliferation of B-cells. MCL presents with a range of morphological variants, which can complicate its diagnosis, although some cases remain straightforward. Clinically, MCL tends to follow an aggressive course, but a less common, indolent leukemia variant has also been observed. Despite its rarity, understanding MCL’s distinct genetic and clinical features is crucial for accurate diagnosis and treatment. The aggressive form of MCL often involves rapid progression, leading to widespread lymphadenopathy, extranodal involvement, and poor prognosis without timely intervention. In contrast, the indolent variant of MCL may present with a more chronic course, sometimes resembling chronic lymphocytic leukemia, and often has a better response to treatment.

Mantle Cell Lymphoma Emerging Drugs Profile

  • Glofitamab: Roche

Glofitamab (Columvi) is a CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. Columvi is designed with a novel 2:1 structural format. This T-cell-engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T cells, a type of immune cell, and two regions that bind to CD20, a protein on B cells, which can be healthy or malignant. This dual-targeting brings the T cell in close proximity to the B cell, activating the release of cancer cell-killing proteins from the T cell. Columvi is being investigated as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma and mantle cell lymphoma. Glofitamab has also been granted Orphan Drug Designation by the US FDA for the treatment of Mantle Cell Lymphoma. Currently, the drug is in Phase III stage of its development for the treatment of Mantle Cell Lymphoma.

  • Zilovertamab vedotin: Merck Sharp & Dohme LLC

Zilovertamab vedotin is an Antibody-Drug Conjugate (ADC) composed of a monoclonal antibody against the Tumor-Associated Antigen (TAA) Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of zilovertamab vedotin targets and binds to ROR1 expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the ROR1-expressing cancer cells, through an as of yet unknown mechanism of action. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and by certain leukemias. It plays key roles in tumor cell proliferation and survival. Currently, the drug is in Phase II stage of its development for the treatment of Mantle Cell Lymphoma.

  • ONM-501: OncoNano Medicine, Inc.

ONM-501 is a dual-activating STING (STimulator of INterferon Genes) agonist delivered to the tumor microenvironment to produce dendritic cell maturation, prime cytotoxic T cells, and induce a strong adaptive immune response. Preclinical data has shown evidence that ONM-501 prolongs STING activation with a low potential for systemic side effects, including cytokine storms. In murine models, ONM-501 has demonstrated antitumor efficacy, and when combined with checkpoint inhibition, produces a synergistic tumor cell death. Currently, the drug is in Phase I stage of its development for the treatment of Mantle Cell Lymphoma.

  • MB 105: March Biosciences

MB-105, selectively targets CD5, a widely expressed antigen both in normal and malignant T-cells. CD5 is a cell surface marker that is commonly expressed in normal T-cells, thymocytes, and a small subset of B-cells. It is widely expressed in T-cell malignancies. It is further highly expressed in T-cell acute lymphoblastic leukemia and certain B-cell malignancies such as Mantle Cell Lymphoma (MCL) and Chronic Leukocytic Leukemia (CLL). The specific engineering of MB-105 CAR enables preservation of normal T-cells, while maintaining cytotoxicity against CD5+ tumor cells, avoiding risk of severe immunodeficiency. CAR T-cell expansion promotes early terminal T-cell differentiation, resulting in potent but short-lived effector cells incapable of driving patient responses. . Currently, the drug is in Preclinical stage of its development for the treatment of Mantle Cell Lymphoma.

If you’re tracking ongoing Mantle Cell Lymphoma Clinical trials @ Mantle Cell Lymphoma Treatment Drugs

The Mantle Cell Lymphoma Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Mantle Cell Lymphoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mantle Cell Lymphoma Treatment.
  • Mantle Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Mantle Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mantle Cell Lymphoma market.

Mantle Cell Lymphoma Companies

Roche, Merck Sharp & Dohme LLC, OncoNano Medicine, Inc., March Biosciences, Wellington Zhaotai Therapies Limited, Regeneron Pharmaceuticals, Nurix Therapeutics, Inc., Cellectar Biosciences, Inc., Adicet Therapeutics, Oncternal Therapeutics, Inc., AstraZeneca, Atara Biotherapeutics, Accutar Biotechnology Inc., AbbVie, Galapagos NV and others.

Mantle Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Mantle Cell Lymphoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

From emerging drug candidates to competitive intelligence, the Mantle Cell Lymphoma Pipeline Report @ Mantle Cell Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Mantle Cell Lymphoma Pipeline Report

  • Coverage- Global
  • Mantle Cell Lymphoma Companies- Roche, Merck Sharp & Dohme LLC, OncoNano Medicine, Inc., March Biosciences, Wellington Zhaotai Therapies Limited, Regeneron Pharmaceuticals, Nurix Therapeutics, Inc., Cellectar Biosciences, Inc., Adicet Therapeutics, Oncternal Therapeutics, Inc., AstraZeneca, Atara Biotherapeutics, Accutar Biotechnology Inc., AbbVie, Galapagos NV and others.
  • Mantle Cell Lymphoma Therapies- Lenalidomide, Obinutuzumab, Glofitamab, Ibrutinib, Rituximab, Ibrutinib, Pirtobrutinib, Acalabrutinib, and others.
  • Mantle Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Mantle Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Mantle Cell Lymphoma treatment landscape in this detailed analysis @ Mantle Cell Lymphoma Emerging Drugs and Major Players

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Mantle Cell Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Mantle Cell Lymphoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Venetoclax: AbbVie
  9. Mid Stage Products (Phase II)
  10. Ixazomib: Takeda
  11. Early Stage Products (Phase I)
  12. PEP07: PharmaEngine
  13. Preclinical and Discovery Stage Products
  14. Product Name: Company Name
  15. Inactive Products
  16. Mantle Cell Lymphoma Key Companies
  17. Mantle Cell Lymphoma Key Products
  18. Mantle Cell Lymphoma- Unmet Needs
  19. Mantle Cell Lymphoma- Market Drivers and Barriers
  20. Mantle Cell Lymphoma- Future Perspectives and Conclusion
  21. Mantle Cell Lymphoma Analyst Views
  22. Mantle Cell Lymphoma Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/mantle-cell-lymphoma-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/mantle-cell-lymphoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mantle Cell Lymphoma Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight

Asthma Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Asthma Pipeline Insight 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Asthma pipeline landscape. It covers the Asthma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Asthma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Learn more about our innovative pipeline today! @ https://www.delveinsight.com/sample-request/asthma-pipeline-insight

Key Takeaways from the Asthma Pipeline Report

  • On May 28, 2026- Arrowhead Pharmaceuticals conducted a phase 2A study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
  • On May 22, 2026- Eli Lilly and Company initiated a phase 2 study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
  • On May 22, 2026- GlaxoSmithKline initiated a phase 2 study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments. GSK5784283 blocks the action of an inflammatory protein called TSLP that may be contributing to your asthma. The study will be conducted in two parts – Part A (dose finding phase) and Part B (extended dosing phase). Part A will assess the lung function, asthma control, participant safety and certain markers of asthma inflammation in the air you breath out and in your blood. Part B will assess the safety and long-term effects of the repeated or single doses of GSK5784283.
  • On May 20, 2026- Sanofi conducted a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period until Week 24 for each participant and an open-label treatment period where each participant will receive open-label amlitelimab from Week 24 onwards. The purpose of this study is to evaluate long-term safety, tolerability, and efficacy of amlitelimab for the treatment of adult participants with moderate-to-severe asthma who have previously been enrolled and completed the treatment period of the parent study. The study duration will be up to 156 weeks. The treatment duration will be up to 144 weeks.
  • On May 19, 2026- Shanghai Novamab Biopharmaceuticals Co., Ltd. announced a phase IIb study includes four periods: a screening period of up to 2 weeks to check eligibility, followed by a 2 week run in period during which all participants take a placebo once daily by nebulizer and record symptoms and rescue medication use. Participants are then randomly assigned to one of three groups for the 24 week treatment period: LQ036 12 mg, LQ036 24 mg, or placebo once daily. For the first 12 weeks, the LQ036 groups are compared with the placebo group; after 12 weeks, those originally on placebo are reassigned to either LQ036 12 mg or 24 mg for the remaining 12 weeks. Throughout the study period, all participants continue their usual asthma controller medicines. A 4 week safety follow up visit occurs after the 24 week treatment to monitor for side effects.
  • On May 18, 2026- AstraZeneca initiated a Phase III study to assess the efficacy and safety of budesonide and albuterol metered dose inhaler (MDI) versus albuterol sulfate (AS) MDI in symptomatic Chinese adults with asthma. Both treatments will be administered as needed in response to asthma symptoms or prior to exercise. Approximately 790 participants who meet the eligibility criteria will be randomized.
  • DelveInsight’s Asthma pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Asthma treatment.
  • The leading Asthma Companies such as AstraZeneca, Enveda, Celldex Therapeutics, SinoMab BioScience Ltd, Anhui Palo Alto Pharmaceuticals, Inc., HUNAN MABGEEK BIOTECH CO., LTD, Chiesi Farmaceutici S.p.A., Arrowhead Pharmaceuticals, Akeso, Keymed Biosciences Co. Ltd, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Pfizer, Ethris GmbH, Windward Bio, Upstream Bio Inc., Jemincare, Longbio Pharma, Kymera Therapeutics, Inc., Avalo Therapeutics, Inc., Haisco Pharmaceutical Group Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., Sanofi, Amgen, Adovate, LLC and others.
  • Promising Asthma Therapies such as HSK31858, Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab, and others.

Stay informed about the cutting-edge advancements in Asthma treatments @ Asthma Clinical Trials Assessment

The Asthma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Asthma Pipeline Report also highlights the unmet needs with respect to the Asthma.

Asthma Overview

Asthma is a prevalent chronic inflammatory respiratory condition affecting millions of people worldwide and presents substantial challenges in both diagnosis and management. This respiratory condition is characterized by inflammation of the airways, causing intermittent airflow obstruction and bronchial hyperresponsiveness. The prevalence and severity of asthma are determined by a complex interplay between genetic and environmental factors. Asthma symptoms vary between individuals and can sometimes worsen into episodes known as asthma attacks, often occurring at night or during physical activity. Common signs include a persistent cough (especially at night), wheezing during breathing, shortness of breath even at rest, and a feeling of chest tightness that makes deep breathing difficult. Symptoms may intensify with triggers such as colds, weather changes, dust, smoke, pollen, or strong odors. Since similar symptoms can arise from other conditions, it is important to consult a healthcare provider for proper evaluation and diagnosis.

Asthma Emerging Drugs Profile

  • GB-0895: Generate:Biomedicines

GB-0895 is an investigational antibody that binds and neutralizes thymic stromal lymphopoietin (TSLP) to help reduce downstream inflammatory signaling in severe asthma. Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine that helps drive airway inflammation and asthma exacerbations. It is engineered for an extended half-life and is being studied for twice-yearly subcutaneous dosing, which may offer administration flexibility and convenience if proven safe and effective. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Asthma.

  • AZD-4604: AstraZeneca

AZD4604 is a potent and selective inhibitor of Janus kinase family member, JAK1, intended for inhaled add-on treatment of moderate to severe asthma, uncontrolled on standard of care. Due to the broad anti-inflammatory properties of JAK1 inhibition, AZD4604 is predicted to provide benefit to steroid sensitive and insensitive asthma endotypes, thereby offering a differentiation opportunity from existing biologics. In a preclinical ovalbumin-challenge rat model of allergic asthma, lung and systemic delivered AZD4604 showed reduction of pSTAT3 and pSTAT5, indicating target engagement in the lung. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Asthma.

  • ENV-294: Enveda

ENV-294 is a novel, first-in-class, small molecule discovered using Enveda’s proprietary platform for the treatment of multiple inflammatory conditions. It targets a novel non-kinase inflammatory pathway distinct from current advanced therapies like JAK-STAT or cytokine signaling, aiming to deliver an oral agent with high efficacy and favorable safety. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Asthma.

  • CDX-622: Celldex Therapeutics

CDX-622 is a bispecific antibody that targets two complementary, clinically validated pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation. SCF activation of the KIT receptor is required for mast cell survival and plays a key role in their activation, maturation and tissue recruitment. Combined neutralization of SCF and TSLP with CDX-622 is expected to simultaneously reduce tissue mast cells and inhibit Type 2 inflammatory responses to potentially offer enhanced therapeutic benefit in inflammatory and fibrotic disorders. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Asthma.

  • SM17: SinoMab BioScience Ltd

SM17 is a novel, first-in-class humanized IgG4-κ monoclonal anƟbody designed to modulate Type II inflammatory responses by targeƟng the receptor of interleukin 25 (IL-25), an “alarmin” molecule central to Type 2 immunity. By binding to the IL-25 receptor (IL-17RB) on Type 2 innate lymphoid cells (ILC2s) and Th2 cells, SM17 blocks IL-25-induced signaling cascades and suppresses downstream cytokines including IL-4, IL-5, and IL-13. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Asthma.

Learn more about Asthma Drugs opportunities in our groundbreaking Asthma Research and development projects @ Asthma Unmet Needs

The Asthma Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Asthma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Asthma Treatment.
  • Asthma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Asthma market.

Asthma Companies

AstraZeneca, Enveda, Celldex Therapeutics, SinoMab BioScience Ltd, Anhui Palo Alto Pharmaceuticals, Inc., HUNAN MABGEEK BIOTECH CO., LTD, Chiesi Farmaceutici S.p.A., Arrowhead Pharmaceuticals, Akeso, Keymed Biosciences Co. Ltd, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Pfizer, Ethris GmbH, Windward Bio, Upstream Bio Inc., Jemincare, Longbio Pharma, Kymera Therapeutics, Inc., Avalo Therapeutics, Inc., Haisco Pharmaceutical Group Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., Sanofi, Amgen, Adovate, LLC and others.

Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

Asthma Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Discover the latest advancements in Asthma treatment by visiting our website @ Asthma Market Drivers and Barriers, and Future Perspectives

Scope of the Asthma Pipeline Report

  • Coverage- Global
  • Asthma Companies- AstraZeneca, Enveda, Celldex Therapeutics, SinoMab BioScience Ltd, Anhui Palo Alto Pharmaceuticals, Inc., HUNAN MABGEEK BIOTECH CO., LTD, Chiesi Farmaceutici S.p.A., Arrowhead Pharmaceuticals, Akeso, Keymed Biosciences Co. Ltd, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Pfizer, Ethris GmbH, Windward Bio, Upstream Bio Inc., Jemincare, Longbio Pharma, Kymera Therapeutics, Inc., Avalo Therapeutics, Inc., Haisco Pharmaceutical Group Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., Sanofi, Amgen, Adovate, LLC and others.
  • Asthma Therapies- HSK31858, Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab, and others.
  • Asthma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Asthma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Asthma Pipeline on our website @ Asthma Emerging Drugs and Companies

Table of Content

1. Introduction

2. Executive Summary

3. Asthma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Asthma – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Mid Stage Products (Phase II)

9. Early Stage Products (Phase I)

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Asthma – Key Companies

13. Asthma – Key Products

14. Asthma – Unmet Needs

15. Asthma – Market Drivers and Barriers

16. Asthma – Future Perspectives and Conclusion

17. Asthma – Analyst Views

18. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/asthma-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/asthma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Asthma Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight

Myasthenia Gravis Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Myasthenia Gravis Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Myasthenia Gravis pipeline landscape. It covers the Myasthenia Gravis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myasthenia Gravis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Myasthenia Gravis Pipeline? @ https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight

Key Takeaways from the Myasthenia Gravis Pipeline Report

  • On May 29, 2026- Amgen conducted a phase 2 study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of inebilizumab administered in pediatric participants with gMG, and to assess the safety and tolerability of inebilizumab administered in pediatric participants with gMG.
  • On May 29, 2026, argenx conducted a phase 3b study is to investigate the efficacy, safety, and tolerability of a continuous regimen of efgartigimod compared with a cyclic regimen in participants with Generalized Myasthenia Gravis (gMG).
  • On May 27, 2026- Novartis Pharmaceuticals initiated a phase III study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate the efficacy, safety and tolerability of remibrutinib in gMG patients who are on stable SOC treatment. Approximately 180 eligible participants will be randomized in a ratio of 1:1, to receive either remibrutinib or matching placebo.
  • On May 22, 2026- UCB Biopharma SRL initiated a study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.
  • On May 22, 2026- Immunovant Sciences GmbH conducted a phase 3 study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
  • On May 19, 2026- Aurinia Pharmaceuticals Inc. announced a clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.
  • DelveInsight’s Myasthenia Gravis Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Myasthenia Gravis treatment.
  • The leading Myasthenia Gravis Companies such as Harbour BioMed (Guangzhou) Co. Ltd., Kyverna Therapeutics, Cabaletta Bio, Takeda, Hoffmann-La Roche, Immunovant Sciences GmbH, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Momenta Pharmaceuticals, Inc., Amgen, Dianthus Therapeutics, Cartesian Therapeutics, COUR Pharmaceutical Development Company, Inc., Alexion Pharmaceuticals, and others.
  • Promising Myasthenia Gravis Therapies such as NMD670, KYV-101, Inebilizumab, Eculizumab, UCB7665, Efgartigimod, Nipocalimab, TAK-079, RVT-1401 and others.

Want to know which companies are leading innovation in Myasthenia Gravis? @ Myasthenia Gravis Clinical Trials Assessment

The Myasthenia Gravis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Myasthenia Gravis Pipeline Report also highlights the unmet needs with respect to the Myasthenia Gravis.

Myasthenia Gravis Overview

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. In MG, the body’s immune system mistakenly attacks receptors on muscle cells, preventing nerve impulses from properly communicating with muscles. This leads to weakness, particularly in muscles that control eye movements, facial expressions, chewing, swallowing, and speaking. However, it can also affect other muscles, including those involved in breathing and limb movements.

Myasthenia Gravis Emerging Drugs

  • HBM9161: Harbour BioMed (Guangzhou) Co. Ltd.

Batoclimab (HBM9161) is a novel, fully human anti-FcRn mAb blocking FcRn-IgG interactions and accelerating the degradation of autoantibodies. The product has the potential to address a variety of pathogenic IgG-mediated autoimmune diseases. Batoclimab is being evaluated for the treatment of patients with severe autoimmune diseases mediated by pathogenic immunoglobulin G (IgG), including generalized myasthenia gravis (gMG), thyroid eye disease (TED), neuromyelitis optica spectrum disorder (NMOSD) and immune thrombocytopenic purpura (ITP). Phase II study in generalized myasthenia gravis showed that batoclimab can quickly and significantly alleviate patients’ symptoms and improve quality of life. Completed studies demonstrated that batoclimab is well tolerated and can rapidly reduce total IgG in a wide array of pathogenic IgG-mediated autoimmune diseases. Currently, the drug is in Preregistration stage of its development for the treatment of Myasthenia Gravis.

  • KYV-101: Kyverna Therapeutics

KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. Kyverna is currently conducting trials of KYV-101 in patients with lupus nephritis, systemic sclerosis, and myasthenia gravis are in preparation. Currently, the drug is in Phase II stage of its development for the treatment of Myasthenia Gravis.

  • CABA-201: Cabaletta Bio

CABA-201 is a fully human CD19 chimeric antigen receptor (CAR) T cell therapy containing a 4-1BB co-stimulatory domain. CABA-201 is designed to deeply and transiently deplete CD19-positive B cells following a one-time infusion, which may enable an “immune system reset” with the potential for durable remission off therapy in patients with autoimmune diseases. To date, Cabaletta has received clearance from the FDA for Investigational New Drug (IND) applications for CABA-201 in multiple autoimmune conditions including systemic lupus erythematosus (SLE), myositis, systemic sclerosis (SSc) and generalized myasthenia gravis (gMG). Cabaletta is conducting four RESET™ Phase I/II clinical trials with a total of nine cohorts that can advance simultaneously, employing a similar parallel cohort design and starting dose of 1 x 106 cells/kg without a dose escalation requirement. Currently, the drug is in Phase I/II stage of its development for the treatment of Myasthenia Gravis.

If you’re tracking ongoing Myasthenia Gravis Clinical trials, this press release is a must-read @ Myasthenia Gravis Treatment Drugs

The Myasthenia Gravis Pipeline report provides insights into:-

  • The report provides detailed insights about companies that are developing therapies for the treatment of Myasthenia Gravis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myasthenia Gravis Treatment.
  • Myasthenia Gravis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Myasthenia Gravis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myasthenia Gravis market.

Myasthenia Gravis Companies

Harbour BioMed (Guangzhou) Co. Ltd., Kyverna Therapeutics, Cabaletta Bio, Takeda, Hoffmann-La Roche, Immunovant Sciences GmbH, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Momenta Pharmaceuticals, Inc., Amgen, Dianthus Therapeutics, Cartesian Therapeutics, COUR Pharmaceutical Development Company, Inc., Alexion Pharmaceuticals, and others.

Myasthenia Gravis Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Myasthenia Gravis Products have been categorized under various Molecule types such as,

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

From emerging drug candidates to competitive intelligence, the Myasthenia Gravis Pipeline Report covers it all @ Myasthenia Gravis Market Drivers and Barriers, and Future Perspectives

Scope of the Myasthenia Gravis Pipeline Report

  • Coverage- Global
  • Myasthenia Gravis Companies- Harbour BioMed (Guangzhou) Co. Ltd., Kyverna Therapeutics, Cabaletta Bio, Takeda, Hoffmann-La Roche, Immunovant Sciences GmbH, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Momenta Pharmaceuticals, Inc., Amgen, Dianthus Therapeutics, Cartesian Therapeutics, COUR Pharmaceutical Development Company, Inc., Alexion Pharmaceuticals, and others.
  • Myasthenia Gravis Therapies- NMD670, KYV-101, Inebilizumab, Eculizumab, UCB7665, Efgartigimod, Nipocalimab, TAK-079, RVT-1401 and others.
  • Myasthenia Gravis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Myasthenia Gravis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Myasthenia Gravis Treatment landscape in this detailed analysis @ Myasthenia Gravis Emerging Drugs and Major Players

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Myasthenia Gravis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Myasthenia Gravis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. HBM9161: Harbour BioMed (Guangzhou) Co. Ltd.
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. KYV-101: Kyverna Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. CABA-201: Cabaletta Bio
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Myasthenia Gravis Key Companies
  21. Myasthenia Gravis Key Products
  22. Myasthenia Gravis- Unmet Needs
  23. Myasthenia Gravis- Market Drivers and Barriers
  24. Myasthenia Gravis- Future Perspectives and Conclusion
  25. Myasthenia Gravis Analyst Views
  26. Myasthenia Gravis Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/myasthenia-gravis-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/myasthenia-gravis-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myasthenia Gravis Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight

Hepatocellular Carcinoma Pipeline Expands as 90+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Hepatocellular Carcinoma Pipeline Insight 2026 report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in the Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Hepatocellular Carcinoma Treatment Landscape @ https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight

Key Takeaways from the Hepatocellular Carcinoma Pipeline Report

  • On May 22, 2026- AstraZeneca conducted a Phase I/II study will evaluate the safety, tolerability, antitumour activity, cellular kinetics, pharmacodynamics, and immunogenicity of AZD5851 in adult participants with GPC3+ advanced/recurrent HCC, where at least one line of prior therapy has failed/or was intolerable, or participant/investigator decision.
  • On May 22, 2026- Shandong Cancer Hospital and Institute announced a study is being conducted to evaluate the efficacy and safety of conversion treatment of Hepatic Arterial Infusion Chemotherapy combined with Camrelizumab and Apatinib for unresected hepatocellular carcinoma.
  • On May 14, 2026- Merck Sharp & Dohme LLC conducted a phase 3 study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS).
  • On May 07, 2026- HepaRegeniX GmbH announced a clinical trial is to learn if HRX215 is safe, tolerable and active in adults who have undergone liver resection due to colorectal carcinoma metastases. A study is designed to evaluate primarily the safety of HRX215, first after minor liver resection and subsequently in participants after major liver resection. Participants undergoing major liver resection will start treatment shortly before liver resection surgery and will receive 28 days of treatment with HRX215 or placebo twice daily with follow up visits at 3 and 6 months.
  • DelveInsight’s Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.
  • The leading Hepatocellular Carcinoma Companies such as Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others
  • Promising Hepatocellular Carcinoma Therapies such as Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab and others.

Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Hepatocellular Carcinoma Clinical Trials Assessment

The Hepatocellular Carcinoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Hepatocellular Carcinoma Pipeline Report also highlights the unmet needs with respect to Hepatocellular Carcinoma.

Hepatocellular Carcinoma Overview

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection. Cirrhosis is a significant step in viral carcinogenesis for hepatocellular carcinoma. Integration of the hepatitis B virus genome into the host genome is the primary pathogenesis for oncogenesis in HBV. Insertion of viral genome in telomerase reverse transcriptase (TERT) promoter sites of the human genome resulting in mutation accounting for 60% of HCC cases. Other genetic alterations include mutations in TP53 (affecting cell cycle), beta-1 catenin (CTNNBI), axis inhibitor-1 (AXINI), AT-rich interaction domain-containing protein 1A (ARID1A), and ARID2(chromatin proliferation).

Hepatocellular Carcinoma Emerging Drugs

• Namodenoson: Can-Fite BioPharma

Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5′- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). The drug had been out-licensed to Chong Kun Dang (CKD) Pharmaceutical in Korea and to CMS in China.for the treatment of Hepatocellular Carcinoma and NASH. A Phase I/II study in hepatocellular carcinoma (HCC) successfully met its primary and secondary endpoints demonstrating initial indications for efficacy of Namodenoson. A global Phase II study treating patients with Namodenoson as a second-line therapy has recently been concluded.

• SRF388: Surface Oncology

SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. IL-27 is an immunosuppressive cytokine involved in resolving T cell mediated inflammation. Recent data points to IL-27 as a master regulator of the expression of co-inhibitory receptors expressed on CD4+ and CD8+ T cells. Elevated levels of IL-27 transcripts and mRNA gene signatures are found in cancer and are associated with poor prognoses. Surface Oncology has identified particular tumor types where IL-27 appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with checkpoint inhibitors.

• Porustobart: Harbour BioMed

Porustobart (HBM4003) is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from mice. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, porustobart has demonstrated significantly improved depletion specific to high CTLA-4 Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combo-therapy.

• Fisogatinib: CStone Pharmaceuticals

Fisogatinib is an orally available, potent, irreversible inhibitor of FGFR4. Fisogatinib was specifically designed to inhibit FGFR4 with exquisite selectivity, thereby sparing the paralogs FGFR1, FGFR2 and FGFR3 and preventing potential adverse effects. Preclinical data has validated FGFR4 as an oncogenic driver for a subset of patients with advanced HCC. The US Food and Drug Administration has granted orphan drug designation to fisogatinib for the treatment of HCC. Fisogatinib is being investigated in the Phase I/II stage of its development for the treatment of patients with FGFR4-activated HCC.

• STP705: Sirnaomics

STP705 is composed of two siRNA oligonucleotides targeting TGF-β1 and COX-2 mRNA respectively and formulated in nanoparticles with a proprietary Histidine-Lysine Co-Polymer (HKP) peptide. Each individual siRNA has demonstrated the ability to inhibit the expression of their target mRNA and combining the two siRNAs produces a synergistic effect that diminishes pro-fibrogenic, pro-inflammatory, and pro-tumorigenic factors. Sirnaomics has completed several pre-clinical studies that demonstrate that inhibition of TGF-β1 and COX-2 and is expected to result in the inhibition of tumor growth and provide an alternative approach for the treatment of various Hepatocellular Carcinomas. Molecular analyses of the effects of administering the combination demonstrated that the inhibition of these targets had effects on downstream gene products associated with numerous oncology targets.

Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Hepatocellular Carcinoma Unmet Needs

The Hepatocellular Carcinoma Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Hepatocellular Carcinoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatocellular Carcinoma Treatment.
  • Hepatocellular Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Hepatocellular Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatocellular Carcinoma market.

Hepatocellular Carcinoma Companies

Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others.

Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

See the latest progress in drug development and clinical research @ Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Hepatocellular Carcinoma Pipeline Report

  • Coverage- Global
  • Hepatocellular Carcinoma Companies- Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others
  • Hepatocellular Carcinoma Therapies- Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab, and others
  • Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Hepatocellular Carcinoma Pipeline Analysis Today! @ Hepatocellular Carcinoma Drugs and Companies

Table of Content

1. Introduction

2. Executive Summary

3. Hepatocellular Carcinoma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Hepatocellular Carcinoma- DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Namodenoson: Can-Fite BioPharma

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. SRF388: Surface Oncology

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I)

14. STP705: Sirnaomics

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. Drug name: Company name

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Hepatocellular Carcinoma Key Companies

21. Hepatocellular Carcinoma Key Products

22. Hepatocellular Carcinoma- Unmet Needs

23. Hepatocellular Carcinoma- Market Drivers and Barriers

24. Hepatocellular Carcinoma- Future Perspectives and Conclusion

25. Hepatocellular Carcinoma Analyst Views

26. Hepatocellular Carcinoma Key Companies

27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/hepatocellular-carcinoma-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/hepatocellular-carcinoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatocellular Carcinoma Pipeline Expands as 90+ Companies Driving Innovation in the Therapeutics | DelveInsight